As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

UK phar­ma gi­ant As­traZeneca on Mon­day un­veiled an­oth­er $140 mil­lion eq­ui­ty in­vest­ment in cell and gene ther­a­py part­ner Cel­lec­tis.

As­traZeneca now owns 44% of Cel­lec­tis’ share cap­i­tal and has 30% of the part­ner’s vot­ing rights. Two As­traZeneca lead­ers, Alex­ion CEO Marc Dunoy­er and cor­po­rate de­vel­op­ment ex­ec­u­tive di­rec­tor Tyrell Rivers, are al­so now on Cel­lec­tis’ board.

As­traZeneca’s in­vest­ment in its Paris-based part­ner was pre­vi­ous­ly planned, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER